journal article·2025-11-11

Rational Design of Aptamer-Guided Framework Nucleic Acid Delivery Platform for Cancer Radionuclide Theranostics

Zhiqiang Ren, Liujun Xu, Jia Liu, Keying Liu, Dali Wei, Qiuyi Li, Weijun Wei, Haitao Zhao, Yifan Lyu, Jianjun Liu, Ding Ding, Weihong Tan

ACS Nano· Volume 19· Issue 44
Publisher page

Abstract

High Resolution Image Download MS PowerPoint Slide DNA aptamers are single-stranded DNA molecules with three-dimensional structures that enable high-affinity and specific binding to target molecules, offering significant potential for precision medicine. Recent advances in DNA nanotechnology have allowed the fabrication of aptamer-guided framework nucleic acid delivery platforms with controllable size and valence. While these platforms have improved tumor delivery in drug delivery, the effects of size and valence on delivery efficacy have not been well studied, particularly in the context of radionuclide-based molecular imaging and therapy. Herein, we fabricate a series of radionuclide-labeled anti-PTK7 aptamer-guided tetrahedron framework nucleic acid delivery platforms (Apt-tFNAs) with varying sizes and valencies. These Apt-tFNAs are well-characterized, and their cell-specific binding ability is demonstrated to be dependent on size and valence. Further in vivo study via dynamic positron emission tomography (PET) scanning reveals that smaller-sized tFNAs improve tumor uptake and reduce liver and kidney retention when valence remains constant. Finally, a single aptamer-modified tFNA with an edge length of 17 bp presents the best tumor delivery efficacy and effective therapeutic performance when combined with either chemotherapy or immunotherapy. This study elucidates how controllable size and valence influence delivery efficacy and introduces optimized Apt-tFNA constructs as promising agents for enhancing targeted therapeutic outcomes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · DNA and Nucleic Acid Chemistry · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Molecular Medicine (IMM), Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital

Shanghai Jiao Tong University School of Medicine

Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine

Shanghai Jiao Tong University

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province

Hunan University

The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou Institute of Medicine (HIM)

Chinese Academy of Sciences

Funding

National Key Research and Development Program of China · Innovative Research Team of High-level Local University in Shanghai · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China

References (43)

Show source-provided references
1. 10.1038/s41587-023-02105-y10.1038/s41587-023-02105-y ↗
2. 10.1038/s43586-022-00104-y10.1038/s43586-022-00104-y ↗
3. 10.1002/anie.20232017910.1002/anie.202320179 ↗
4. 10.1021/acs.chemrev.3c0037710.1021/acs.chemrev.3c00377 ↗
5. 10.1021/acs.accounts.1c0072410.1021/acs.accounts.1c00724 ↗
6. 10.1021/jacs.4c0074810.1021/jacs.4c00748 ↗
7. 10.1016/j.bios.2022.11415910.1016/j.bios.2022.114159 ↗
8. 10.1038/s41467-020-15113-210.1038/s41467-020-15113-2 ↗
9. 10.1073/pnas.240406012110.1073/pnas.2404060121 ↗
10. 10.1016/j.bioactmat.2022.05.01610.1016/j.bioactmat.2022.05.016 ↗
11. 10.1021/acs.chemrev.0c0114010.1021/acs.chemrev.0c01140 ↗
12. 10.1016/j.tibtech.2023.05.00510.1016/j.tibtech.2023.05.005 ↗
13. 10.1021/acsnano.2c1037910.1021/acsnano.2c10379 ↗
14. 10.1002/adma.20210782010.1002/adma.202107820 ↗
15. 10.1021/acs.nanolett.1c0500310.1021/acs.nanolett.1c05003 ↗
16. 10.1002/anie.20190934510.1002/anie.201909345 ↗
17. 10.1016/j.nantod.2023.10212710.1016/j.nantod.2023.102127 ↗
18. 10.1038/s41596-022-00791-710.1038/s41596-022-00791-7 ↗
19. 10.1021/acsnano.3c0699910.1021/acsnano.3c06999 ↗
20. 10.1038/s41568-023-00576-410.1038/s41568-023-00576-4 ↗
21. 10.1007/s00259-022-06084-110.1007/s00259-022-06084-1 ↗
22. 10.1007/s00259-023-06174-810.1007/s00259-023-06174-8 ↗
23. 10.2967/jnumed.120.24329510.2967/jnumed.120.243295 ↗
24. 10.1016/j.radphyschem.2022.11034210.1016/j.radphyschem.2022.110342 ↗
25. 10.34133/research.012610.34133/research.0126 ↗
26. 10.1007/s00259-022-05782-010.1007/s00259-022-05782-0 ↗
27. 10.1016/S1470-2045(23)00525-910.1016/S1470-2045(23)00525-9 ↗
28. 10.1002/adfm.20230555810.1002/adfm.202305558 ↗
29. 10.1002/smll.20230232610.1002/smll.202302326 ↗
30. 10.1021/acsnano.3c0585310.1021/acsnano.3c05853 ↗
31. 10.1093/nar/gkaa68310.1093/nar/gkaa683 ↗
32. 10.1016/j.addr.2020.11.01010.1016/j.addr.2020.11.010 ↗
33. 10.1002/smll.20230469310.1002/smll.202304693 ↗
34. 10.1002/advs.20230824810.1002/advs.202308248 ↗
35. 10.1016/j.matt.2024.10.02010.1016/j.matt.2024.10.020 ↗
36. 10.1038/s41388-024-03060-x10.1038/s41388-024-03060-x ↗
37. 10.1021/acsnano.4c0829310.1021/acsnano.4c08293 ↗
38. 10.1080/10717544.2025.251295010.1080/10717544.2025.2512950 ↗
39. 10.1021/acsnano.4c0829310.1021/acsnano.4c08293 ↗
40. 10.1039/D1CS01070K10.1039/D1CS01070K ↗
41. 10.1038/s44222-023-00138-110.1038/s44222-023-00138-1 ↗
42. 10.1200/JCO.20.0193210.1200/JCO.20.01932 ↗
43. 10.1038/s41467-023-43462-110.1038/s41467-023-43462-1 ↗